Literature DB >> 8025661

Selective iron deposition in pancreatic islet B cells of transfusional iron-overloaded autopsy cases.

J P Lu1, K Hayashi.   

Abstract

Pancreatic islets of 36 autopsy cases with transfusional iron-overload were examined. Immunohistochemical and histochemical stainings were used to clarify the relationship between blood transfusion and iron deposition in the islet. Disease of the lymphohemopoietic system (leukemia, lymphoma, aplastic anemia) or liver (carcinoma and/or cirrhosis) accounted for 86.1% of the patients' main diagnosis. Sixteen of them had slight hemosiderin deposition (Group 1), twenty cases had severe hemosiderin deposition (Group 2). Another ten cases were used as controls (Group 3). The cases had a similar age distribution to Group 1 and 2, with neither blood transfusion nor hemosiderin deposition. The volume of blood transfusion was 6.1 +/- 3.6, 17.5 +/- 12.2 L for Groups 1 and 2, respectively. The plasma glucose was 137.8 +/- 54.4 and 170.6 +/- 108.4 mg/dL, respectively. Four cases in Group 1 and 14 cases in Group 2 had glycosuria. The number of islet cells with hemosiderin increased with the enlargement of transfusion volume (r = 0.664, P < 0.001). Plasma glucose also related with the percentage of hemosiderin positive islet cell (r = 0.386, P < 0.025). In severely iron-overloaded cases, hemosiderin was selectively deposited in B cells of the islet. It was concluded that large amounts of blood transfusions for non-congenital disease can induce selective hemosiderin deposition and impairment of pancreatic B cell that may result in hyperglycemia and diabetes mellitus of the patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025661     DOI: 10.1111/j.1440-1827.1994.tb02592.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  8 in total

Review 1.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

2.  ROS-triggered degradable iron-chelating nanogels: Safely improving iron elimination in vivo.

Authors:  Zhi Liu; Jing Qiao; Tamas Nagy; May P Xiong
Journal:  J Control Release       Date:  2018-05-22       Impact factor: 9.776

3.  The plasma membrane metal-ion transporter ZIP14 contributes to nontransferrin-bound iron uptake by human β-cells.

Authors:  Richard Coffey; Mitchell D Knutson
Journal:  Am J Physiol Cell Physiol       Date:  2016-11-30       Impact factor: 4.249

Review 4.  Pancreatic iron quantification with MR imaging: a practical guide.

Authors:  Antonella Meloni; Vincenzo Positano; Laura Pistoia; Filippo Cademartiri
Journal:  Abdom Radiol (NY)       Date:  2022-05-21

5.  Quantification of pancreatic iron overload and fat infiltration and their correlation with glucose disturbance in pediatric thalassemia major patients.

Authors:  Jingwen Huang; Jun Shen; Qihua Yang; Ziliang Cheng; Xiaodong Chen; Taihui Yu; Jinglian Zhong; Yun Su; Hua Guo; Biling Liang
Journal:  Quant Imaging Med Surg       Date:  2021-02

6.  The Frequency of Adrenal Insufficiency in Adolescents and Young Adults with Thalassemia Major versus Thalassemia Intermedia in Iran.

Authors:  Sara Matin; Masoud Ghanei Jahromi; Zohreh Karemizadeh; Sezaneh Haghpanah; Vincenzo De Sanctis; Ashraf Soliman; Javad Dehbozorgian; Zahra Majd; Narges Rezaei; Mehran Karimi
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-01-01       Impact factor: 2.576

7.  Comparative study on hemoglobin A1c, glycated albumin and glycosylated serum protein in aplastic anemia patients with Type 2 diabetes mellitus.

Authors:  Minghuan Suo; Dongmei Wen; Weijia Wang; Tingting Zhang
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

Review 8.  The (Bio)Chemistry of Non-Transferrin-Bound Iron.

Authors:  André M N Silva; Maria Rangel
Journal:  Molecules       Date:  2022-03-09       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.